Mechanistic Insights for Optimizing PSMA Radioligand Therapy

Aravind S Ravi Kumar; Michael S Hofman

doi:10.1158/1078-0432.CCR-20-0209

Mechanistic Insights for Optimizing PSMA Radioligand Therapy

Clin Cancer Res. 2020 Jun 15;26(12):2774-2776. doi: 10.1158/1078-0432.CCR-20-0209. Epub 2020 Apr 6.

Authors

Aravind S Ravi Kumar^{1

2}, Michael S Hofman^{1

2}

Affiliations

¹ Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. aravind.ravikumar@petermac.org michael.hofman@petermac.org.
² The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.

PMID: 32253231
DOI: 10.1158/1078-0432.CCR-20-0209

Abstract

PSMA radioligand therapy is a promising new class of therapy for prostate cancer. Heterogeneity of PSMA expression is an important factor explaining variability in clinical results. The ability to visualize the target with theranostics provides unique mechanistic insights. Potential clinically applicable strategies to improve patient selection and optimize therapeutic efficacy are discussed.See related article by Current et al., p. 2946.

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Comment

MeSH terms

Humans
Male
Patient Selection
Precision Medicine
Prostatic Neoplasms* / radiotherapy
Theranostic Nanomedicine